Department of Radiology, Mater Misericordiae University Hospital, Dublin, Ireland.
AJNR Am J Neuroradiol. 2011 Nov-Dec;32(10):1830-5. doi: 10.3174/ajnr.A2656. Epub 2011 Sep 22.
Transforaminal CS injections have been associated with severe adverse CNS events, including brain and spinal cord infarction. Our purpose was to describe the static and dynamic microscopic appearances of CS preparations, with an emphasis on their potential to cause adverse central nervous system events by embolic mechanisms during transforaminal injection.
Pharmaceutical preparations of nondilute injectable CSs were used after appropriate mixing: MPA (40 mg/mL), TA (40 mg/mL), and DSP (8 mg/2 mL). For dynamic imaging, a novel methodology was devised to replicate the flow of crystals within spinal cord arterioles. In addition, CS preparations were mixed with plasma to assess for changes in crystal size, morphology, and tendency to aggregate.
The CS preparations MPA and TA are composed of crystals of varying sizes. MPA crystal size range was 0.4-26 μm (mean, 6.94 μm), TA crystal size range 0.5-110 μm (mean, 17.4 μm), and DSP did not contain any significant crystals or particles. There was no change in the crystal morphology or propensity to aggregate after mixing with local anesthetic. After mixing with plasma, the crystals also were unchanged; however, there was a significant reduction in the size of aggregates. On dynamic imaging, these aggregates were proved to maintain their integrity and to act as potential embolization agents.
MPA and TA have a substantial risk of causing infarction by embolization if inadvertently injected intra-arterially at the time of TFESI. DSP is completely soluble and microscopically has no potential to obstruct arterioles. When performing cervical TFESI procedures, the administration of insoluble CSs should be avoided.
经椎间孔脊神经根阻滞注射已与严重不良中枢神经系统事件相关联,包括脑和脊髓梗死。我们的目的是描述脊神经根阻滞注射时,CS 制剂的静态和动态微观表现,重点强调其通过栓塞机制引起不良中枢神经系统事件的潜在可能性。
对非稀释可注射 CS 制剂进行适当混合后使用:MPA(40mg/mL)、TA(40mg/mL)和 DSP(8mg/2mL)。为了进行动态成像,设计了一种新的方法学来复制脊髓小动脉内晶体的流动。此外,将 CS 制剂与血浆混合,以评估晶体大小、形态和聚集趋势的变化。
CS 制剂 MPA 和 TA 由不同大小的晶体组成。MPA 晶体大小范围为 0.4-26μm(平均 6.94μm),TA 晶体大小范围为 0.5-110μm(平均 17.4μm),而 DSP 不含任何显著的晶体或颗粒。与局部麻醉剂混合后,晶体形态或聚集倾向没有变化。与血浆混合后,晶体也没有变化;然而,聚集物的大小显著减小。在动态成像中,这些聚集物被证明保持其完整性,并作为潜在的栓塞剂。
如果在 TFESI 时无意中经动脉内注射,MPA 和 TA 有实质性的引起梗死的栓塞风险。DSP 完全可溶,微观上没有阻塞小动脉的潜力。在进行颈椎 TFESI 手术时,应避免使用不溶性 CS 制剂。